# Trade Mark Journal No.2026/017 24 April 2026

## WO0000001899698 (5)

Office of origin: United States of America

Date of International Registration:19 December 2025
Date of designation in the UK: 19 December 2025

International priority date claimed: 20 June 2025 (United States of America) (99245336)

Class 5
  Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

SFJ Pharma X, Inc.

Representative: Muzamil Huq Morrison & Foerster LLP, 425 Market Street, Suite #3200, San Francisco CA 94105, UNITED STATES OF AMERICA